



**Health Research Authority**  
**National Research Ethics Service**

**NRES Committee London - South East**

Barlow House  
3rd Floor  
4 Minshull Street  
Manchester  
M1 3DZ

17 August 2015

Michael Stringer  
Clinical Trial Coordinator  
Stroke, Division of Clinical Neuroscience  
School of Medicine  
Faculty of Medicine and Health Sciences  
Clinical Sciences Building  
University of Nottingham  
City Hospital Campus  
Hucknall Road  
Nottingham  
NG5 1PB

Dear Dr Stringer

**Study title:** Safety and tolerability of clopidogrel when added to aspirin and dipyridamole in high risk patients with recent ischaemic stroke: a randomised controlled trial

**REC reference:** 08/H1102/112

**Protocol number:** 31350

**EudraCT number:** 2007-006749-42

**Amendment number:** SA03/15

**Amendment date:** 14 August 2015

**IRAS project ID:**

The Substantial Amendment adds the following sites to the study;

- Kent and Canterbury Hospital - PI Hardeep Baht
- North Middlesex University Hospital - PI Robert Luder

Thank you for submitting the above amendment, which was received on 17 August 2015.

<i>Research site</i>	<i>Principal Investigator / Local Collaborator</i>
Kent and Canterbury Hospital	Hardeep Baht
North Middlesex University Hospital	Robert Luder

The amendment relates solely to the addition of new sites and investigators within the National Health Service (NHS) or Health and Social Care (HSC) in Northern Ireland. The site-specific assessment for the site(s) will therefore form part of the research governance review. The Site-Specific Information (SSI) Form for the site should be included with the application for R&D approval.

On behalf of the Committee, I am pleased to confirm the extension of the favourable opinion to the new sites and investigators, subject to management permission being given by the relevant NHS/HSC R&D office(s) prior to the study starting at the site.

### **Statement of compliance**

This Committee is recognised by the United Kingdom Ethics Committee Authority under the Medicines for Human Use (Clinical Trials) Regulations 2004, and is authorised to carry out the ethical review of clinical trials of investigational medicinal products.


The Committee is fully compliant with the Regulations as they relate to ethics committees and the conditions and principles of good clinical practice.

The Committee is constituted in accordance with the Governance Arrangements for Research Ethics Committees and complies fully with the Standard Operating Procedures for Research Ethics Committees in the UK.

**08/H1102/112**

**Please quote this number on all correspondence**

Yours sincerely



**Katie Southeard**  
**REC Assistant**

Email: [nrescommittee.london-southeast@nhs.net](mailto:nrescommittee.london-southeast@nhs.net)

Copy to: *Professor Philip M. W. Bath, University of Nottingham*